This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Repetitive Versus Deep Transcranial Magnetic Stimulation for Major Depression (ReDeeMD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05902312
Recruitment Status : Recruiting
First Posted : June 13, 2023
Last Update Posted : April 18, 2024
Sponsor:
Collaborator:
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
Centre hospitalier de l'Université de Montréal (CHUM)

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The goal of this randomized controlled trial is to he effectiveness of two different TMS techniques in TRD, repetitive TMS (rTMS) and deep TMS (dTMS). The main questions it aims to answer are:

type of study: clinical trial participant population/health conditions : Major Depressive Disorder To assess the superiority of dTMS over rTMS in TRD To evaluate the predictive capacity of scalable candidate biomarkers Participants will be randomly allocated to one of the two intervention groups (rTMS or dTMS).


Condition or disease Intervention/treatment Phase
Major Depressive Disorder Device: transcranial magnetic stimulation Not Applicable

Detailed Description:
The primary aim of this trial is to compare the effectiveness of two different TMS techniques in TRD, repetitive TMS (rTMS) and deep TMS (dTMS). Compared to rTMS, dTMS delivers a broader magnetic field, which in turn reduces coil positioning error and maximizes the probability of optimal cortical stimulation. A past RCT comparing both approaches found a greater depression score decrease and response/remission rates for dTMS, but was short of reaching significance for remission rates (primary outcome). Critical components of this RCT were suboptimal, including too few treatment sessions and insufficient statistical power, both of which could have obscured an actual difference between modalities. Proof of a more effective type of TMS over another would translate into increased odds of improvement for TRD patients who live with a chronic and disabling illness.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: randomized, single-center, two-arm, parallel-group superiority trial
Masking: Single (Outcomes Assessor)
Masking Description: Given the study's design, blinding participants and TMS operators will not be possible. Still, staff responsible for participant assessments and data analysis will be blinded to treatment conditions and external to the clinic staff. Patients will be instructed not to reveal their group assignment to the raters. Patients will not be given the specifics of the treatment parameters and will be instructed not to talk to each other during the study period. Both treatments will be presented as effective to them. Lastly, the data management center will strictly control access to the randomization code.
Primary Purpose: Treatment
Official Title: Comparative Effectiveness of Repetitive Versus Deep Transcranial Magnetic Stimulation for Major Depression: A Randomized Controlled Trial
Actual Study Start Date : January 1, 2024
Estimated Primary Completion Date : January 1, 2026
Estimated Study Completion Date : September 1, 2027

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: repetitive Transcranial Magnetic Stimulation
rTMS on a MagPro X100 research grade stimulator (MagVenture) equipped with a B70 fluid-cooled coil. Participant will receive the MDD FDA-approved iTBS protocol (triplet 50 Hz bursts repeated at 5 Hz, 2 s ON and 8 s OFF; 600 pulses per session; total duration of 3 min 9 s, 120% hand motor threshold)
 Device: transcranial magnetic stimulation
Participants will receive either rTMS or dTMS
Other Name: deep transcranial magnetic stimulation
Experimental: deep Transcranial Magnetic Stimulation
dTMS on a research Brainsway system equipped with an H7-Coil. Participants will receive the MDD FDA-cleared 18 Hz stimulation protocol (2 sec ON, 20 sec OFF, 55 trains; 1980 pulses per session; 20 min 10 s duration; 120% hand motor threshold)
 Device: transcranial magnetic stimulation
Participants will receive either rTMS or dTMS
Other Name: deep transcranial magnetic stimulation


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Hamilton Rating Scale for Depression-17 (HRSD-17) [ Time Frame: Baseline to Week 6 ]
    score change. Higher score means worse outcome. (Min = 0, Max = 53)

  2. Response (yes/no) on Hamilton Rating Scale for Depression-17 [ Time Frame: baseline to Week 6 ]
    Defined as a score reduction of 50% or more

  3. Remission (yes/no) on Hamilton Rating Scale for Depression-17 [ Time Frame: Week 6 ]
    Defined as a score of 7 or less


Secondary Outcome Measures :
  1. Hamilton Rating Scale for Depression-17 [ Time Frame: Baseline to Week 7 ]
    score change. Higher score means worse outcome. (Min = 0, Max = 53)

  2. Hamilton Rating Scale for Depression-17 [ Time Frame: Baseline to Week 10 ]
    score change. Higher score means worse outcome. (Min = 0, Max = 53)

  3. Hamilton Rating Scale for Depression-17 [ Time Frame: Baseline to Week 18 ]
    score change. Higher score means worse outcome. (Min = 0, Max = 53)

  4. Response (yes/no) on Hamilton Rating Scale for Depression-17 [ Time Frame: Baseline to Week 7 ]
    Defined as a score reduction of 50% or more

  5. Response (yes/no) on Hamilton Rating Scale for Depression-17 [ Time Frame: Baseline to Week 10 ]
    Defined as a score reduction of 50% or more

  6. Response (yes/no) on Hamilton Rating Scale for Depression-17 [ Time Frame: Baseline to Week 18 ]
    Defined as a score reduction of 50% or more

  7. Remission (yes/no) on Hamilton Rating Scale for Depression-17 [ Time Frame: Baseline to Week 7 ]
    Defined as a score of 7 or less

  8. Remission (yes/no) on Hamilton Rating Scale for Depression-17 [ Time Frame: Baseline to Week 10 ]
    Defined as a score of 7 or less

  9. Remission (yes/no) on Hamilton Rating Scale for Depression-17 [ Time Frame: Baseline to Week 18 ]
    Defined as a score of 7 or less

  10. Hamilton Rating Scale for Depression-28 [ Time Frame: Baseline to Week 6, Week 7, Week 10, Week 18 ]
    score change. Higher score means worse outcome. (Min = 0, Max = 90)

  11. Hamilton Anxiety Rating Scale (HAM-A) [ Time Frame: Baseline to Week 6, Week 7, Week 10, Week 18 ]
    score change. Higher score means worse outcome. (Min = 0, Max = 56)

  12. Quick Inventory of Depressive Symptomatology (self-report) (QIDS-SR 16) [ Time Frame: Baseline to Week 6, Week 7, Week 10, Week 18 ]
    score change. Higher score means worse outcome. (Min = 0, Max = 42)

  13. General Anxiety Disorder-7 (GAD-7) [ Time Frame: Baseline to Week 6, Week 7, Week 10, Week 18 ]
    score change. Higher score means worse outcome. (Min = 0, Max = 21)

  14. Snaith-Hamilton Pleasure Scale (SHAPS) [ Time Frame: Baseline to Week 6, Week 7, Week 10, Week 18 ]
    score change. Higher score means worse outcome. (Min= 0, Max = 56)

  15. Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: Baseline to Week 6, Week 7, Week 10, Week 18 ]
    score change. Higher score means worse outcome. (Min = 0, Max = 30)

  16. Rumination Response Scale (RRS) [ Time Frame: Baseline to Week 6, Week 7, Week 10, Week 18 ]
    score change. Higher score means worse outcome. (Min = 0, Max = 88)

  17. Adult AHDH Self-Report Scale [ Time Frame: Baseline to Week 18 ]
    qualitative.

  18. McLean Screening Instrument for Borderline Personality Disorder [ Time Frame: Baseline ]
    score. Higher score means worse outcome. (Min = 0, Max = 10)

  19. World Health Organization Quality of Life Short Version (WHOQOL-BREF) [ Time Frame: Baseline to Week 6, Week 7, Week 10, Week 18 ]
    Difference score. Lower score means worse outcome. (Min = 26, Max = 130)

  20. Cognitive Difficulties Scale (MacNair-R) [ Time Frame: Baseline to Week 6, Week 7, Week 10, Week 18 ]
    Difference score. Higher score means worse outcome. (Min = 0, Max = 156)

  21. Memory Complaints Scale (MacNair) [ Time Frame: Baseline to Week 6, Week 7, Week 10, Week 18 ]
    score. Higher score means worse outcome. (Min = 0, Max = 45)

  22. Visual Pain Scale [ Time Frame: Each treatment day ]
    Maximum score (during treatment). Higher score means worse outcome. (Min = 0, Max = 10).

  23. Sex and Gender scale [ Time Frame: Baseline ]
    Descriptive statistics


Other Outcome Measures:
  1. Electroencephalogram to predict treatment response [ Time Frame: Baseline ]
    individual alpha frequency

  2. Electroencephalogram event-related potentials [ Time Frame: Baseline ]
    Reward positivity

  3. Electrocardiogram [ Time Frame: Baseline ]
    corrected QT interval

  4. Pupil measures [ Time Frame: Baseline ]
    pupil reactivity measures


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Major Depressive Disorder, at least moderate intensity, single or recurrent episode
  • HRSD-17 score of at least 18
  • No improvement to at least two adequate courses of antidepressants (based on the ATHF) or were unable to tolerate at least two separate trials of antidepressants of inadequate dose and duration
  • On a stable antidepressant regimen for the past four weeks before screening
  • Patients with a chronic depressive episode >2 years and who have previously received ECT or ketamine will be eligible to participate

Exclusion Criteria:

  • Having previously received TMS;
  • Substance use disorder within the last three months
  • Diagnosis of bipolar or psychosis spectrum disorder
  • Anxiety or personality disorder that is assessed by a study investigator to be the primary cause and causing greater impairment than MDD
  • Concomitant major unstable medical or neurological illness
  • Intracranial implant, cardiac pacemaker or implanted medication pump
  • Significant laboratory abnormality;
  • Active suicidal intent
  • Pregnancy
  • If participating in psychotherapy, must have been in stable treatment for at least three months before entry into the study, with no anticipation of change
  • Currently taking more than the equivalent of 2 mg of lorazepam of a benzodiazepine daily or any dose of an anticonvulsant due to the potential to limit TMS effectiveness
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05902312


Contacts
Layout table for location contacts
Contact: Jean-Philippe Miron, MD PhD 514-890-8000 ext 26489 jean-philippe.miron@umontreal.ca
Contact: Véronique Desbeaumes Jodoin, PhD 514-890-8000 ext 26489 vdesbeaumes@gmail.com

Locations
Layout table for location information
Canada, Quebec
CHUM Recruiting
Montréal, Quebec, Canada, H2X 0C1
Contact: Véronique Desbeaumes, Ph.D.         
Contact: Sylvie Tieu, B.Sc         
Sponsors and Collaborators
Centre hospitalier de l'Université de Montréal (CHUM)
Canadian Institutes of Health Research (CIHR)
Investigators
Layout table for investigator information
Principal Investigator: Jean-Philippe Miron, MD PhD Centre de Recherche du Centre Hospitalier de l'Université de Montréal
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Centre hospitalier de l'Université de Montréal (CHUM)
ClinicalTrials.gov Identifier: NCT05902312    
Other Study ID Numbers: 2023-11389
First Posted: June 13, 2023    Key Record Dates
Last Update Posted: April 18, 2024
Last Verified: April 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Centre hospitalier de l'Université de Montréal (CHUM):
MDD
TMS
deep TMS
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Major
Mood Disorders
Mental Disorders